Kornimate/medical-research-clean huggingface dataset:
prevalence , risk factors and outcomes of aki in icu patients

Conditions: Acute Kidney Injury

Summary: early recognition of aki is essential to ensure prompt and appropriate management, and to avoid progression to late stages of the disease (2) aki requiring renal replacement therapy occurs in 5-6% of icu patients, with an extremely high in hospital mortality rate of 60%.6 it is estimated that about 2 million people die of aki every year. those who survive aki have a higher risk for later development of ckd(3). epidemiology of aki is understudied in developing countries so further studies are needed to estimate the burden of aki among icu patients. few studies about the epidemiology of aki in egypt were done;

acute kidney injury is a sudden episode of kidney failure or damage that happens within a few hours or days. according to kdigo (kidney disease improving global outcomes) criteria: aki is defined as any of the following: increase in serum creatinine by 0.3mg/dl or more within 48 hours or. increase in serum creatinine to 1.5 times baseline or more within the last 7 days or. urine output less than 0.5 ml/kg/h for 6 hours(1). kidney injury (aki) affects over 13 million people per year globally and results in 1.7 million deaths. recent hospital studies in the developed world report aki in 3.2-9.6% of admissions, with overall in-hospital mortality around 20%, and up to 50% in icu patients. early recognition of aki is essential to ensure prompt and appropriate management, and to avoid progression to late stages of the disease (2) aki requiring renal replacement therapy occurs in 5-6% of icu patients, with an extremely high in hospital mortality rate of 60%.6 it is estimated that about 2 million people die of aki every year. those who survive aki have a higher risk for later development of ckd(3). epidemiology of aki is understudied in developing countries so further studies are needed to estimate the burden of aki among icu patients. few studies about the epidemiology of aki in egypt were done; samar abd elhafeez e,tal 2017 found in a multicenter study of over 500 consecutive patients admitted to icus in alexandria teaching hospitals in egypt, that about 40% of patients admitted to icu had aki at presentation, and a similar proportion of those who were aki-free on admission developed aki during their icu stay (4) . up to our knowledge, there are no sufficient data about the epidemiology of aki in upper egypt

Eligibility criteria:
inclusion criteria: * all patients \>18 years admitted to medical icu in internal medicine department with critical medical conditions who develop aki during hospital admission or presented with aki exclusion criteria: * patients with esrd on regular dialysis ,patients with stage 4 or 5 non-dialysis if the condition proven to be progression of the already known diagnosis.
gta-glyceryltriacetate for canavan disease

Conditions: Infantile Canavan Disease; Deficiency Disease, Aspartoacylase

Summary: the purpose of this study is to determine whether oral supplementation of glyceryl triacetate improves the clinical prognosis of canavan disease.

canavan disease is caused by a deficiency in the enzyme named aspartoacylase (aspa). this disease is a devastating, progressive disease with no available treatment. as a result of the aspa deficiency, there are high levels of n-acetylaspartate (naa) and low levels of l-aspartate and acetate. we hypothesize that one of the functions of aspa is to provide sufficient levels of acetate for cns myelinization. for this reason, we offer to supplement acetate levels by the oral administration of glyceryl triacetate (gta). such treatment must be offered to patients before the age of 18 months, prior to the termination of cns myelinization. 1. two patients, aged less than 15 months, will receive daily doses of oral gta 2. the daily dose will be increased incrementally until the maintenance dose is reached. this will be done under close monitoring of the patients, including periodic blood gas sampling. 3. gta has not been shown to cause any known toxicity, according to the cosmetic ingredient review expert panel (fiume, 2003).

Eligibility criteria:
inclusion criteria: * age below 15 months * biochemically diagnosed with canavan disease exclusion criteria: * none

Keywords: canavan disease aspartoacylase deficiency naa acetate glyceryltriacetate
evaluation of urinary dysfunction in canvas patients

Conditions: Cerebellar Ataxia; Neuropathy; Vestibular Areflexia

Summary: the investigator wishes to evaluate the prevalence of urinary symptoms in patients diagnosed with cerebellar ataxia, neuropathy, vestibular areflexia syndrome (canvas). as much as one third of patients living with canvas experience symptoms of urinary system dysfunction. the primary objective of this study is to evaluate the incidence of urinary symptoms in these patients, as well as the potential complications that might occur at the level of the upper and lower urinary system. the investigator also wishes to analyse the connection between the severity of the neurological deficits, the presence of dysautonomia and the presence of urinary dysfunction. to that end, the data collected in the study will concern : a detailed neurological examination including sara (scale for the assessement and rating of ataxia) scale assessement, laboratory tests of the renal function, dysautonomia tests with sudoscan and research of orthostatic hypotension, urinary function questionnaires, dysautonomia questionnaire, urodynamic tests and urinary system ultrasound.


Eligibility criteria:
inclusion criteria: * 18 years old and more * genetic confirmation of canvas (presence of pathogenic penta nucleotide expansion in both alleles of the replication factor c subunit 1(rfc1) gene or pathological penta nucleotide expansion in the heterozygous state associated with a truncating mutation on the second allele of the rfc1 gene) * able to undergo renovesical ultrasound and urinary flow measurement; * having given informed consent in writing; * negative pregnancy test for people on childbearing age; * social security affiliated exclusion criteria: * presenting another urological pathology of base, not related to canvas; * having undergone a urological intervention within the 6 months preceding the screening visit; * presenting a condition that is incompatible with the proper conduct of the study as determined by the physician; * protected by law under guardianship or curators, or not able to participate in a clinical study pursuant to article l. 1121-16 of the french public health code * pregnant or breastfeeding women for women of childbearing age
pet (positron emission tomography)/public speaking study with a combination of 2 medications in social anxiety patients

Conditions: Depressive Disorder and Anxiety Disorders

Summary: this six-arm study is being conducted to measure the effect of a combination of paroxetine and vestipitant on the arousal induced by public speaking in seasonal effective disorder (sad) patients, using functional brain imaging readouts (i.e., wat(wave analysis technology) pet(positron emission tomography)), after one or eight weeks of treatment. the effect of paroxetine alone after one or eight weeks of treatment will also be measured.

a double-blind, double dummy, placebo-controlled, randomised, parallel group positron emission tomography study to investigate the effects of a 8 week administration of vestipitant and paroxetine in combination or paroxetine alone on regional cerebral blood flow during a public speaking test in subjects affected by social anxiety disorder.

Eligibility criteria:
inclusion criteria: * social phobic ambulatory subjects, defined according to dsm-iv criteria. * must be capable of giving informed consent and can comply with the study requirements. * women of childbearing potential must agree to acceptable method of birth control. exclusion criteria: * primary diagnosis within the past 6 months of other psychiatric conditions such as major depression or another anxiety disorder. * use of medications for a psychiatric condition including herbals in the past 2-12 weeks according to medication type. * subjects who, in the investigator's judgement pose a current, serious suicidal or homicidal risk or have made a suicide attempt within the past 6 months. * subjects who currently meet or who met within 6 months prior to screening dsm-iv criteria for substance abuse or subjects who currently meet or who met within 6 months prior to screening dsm-iv criteria for substance dependence (other than nicotine). * significantly abnormal blood or urine laboratory tests or electrocardiogram (ecg) findings.

Keywords: social anxiety disorder brain imaging positron emission tomography antidepressant
phase 1 study to evaluate pk, safety, and tolerability of hrs-5041 in healthy caucasian male participants

Conditions: Prostate Cancer

Summary: this is a phase 1, open-label, randomized study. the objective of this study is to evaluate the pk, safety and tolerability of orally administered single-dose hrs-5041 in healthy caucasian male participants.

the objective of this study is to evaluate the pk, safety and tolerability of orally administered single-dose hrs-5041 in healthy caucasian male participants.

Eligibility criteria:
inclusion criteria: 1. healthy caucasian participants; 2. ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial, 3. male aged between 18 to 55 years of age (inclusive) at the date of signed consent form. 4. total body weight ≥ 50.0 kg, body mass index (bmi) between 19.0 and 32.0 kg/m2 (inclusive) at screening. exclusion criteria: 1. history of receiving any androgen receptor (ar) degraders. 2. history or evidence of clinically significant 3. history of severe abnormal gastric emptying, severe gastrointestinal (gi) disease, or participants who had gi surgeries (except gi polypectomy). 4. severe infections, injuries, or major surgeries as determined by the investigator within 6 months 5. any other circumstances (e.g., not suitable for venous access) or laboratory abnormality that, in the investigator's judgment, may increase the risk to the participant, or be associated with the participant's participation in and completion of the study or could preclude the evaluation of the participant's response.
frailty assessment before cardiac surgery & transcatheter interventions

Conditions: Aortic Stenosis; Cardiac Valve Replacement Complication; Fragility

Summary: frailty is a state of decreased physiologic reserves and vulnerability to stressors. several tools exist to measure frailty, some based on physical tests and others on questionnaires, yet there is no agreement on which tool to recommend. this multi-center prospective cohort study is aimed at comparing various frailty assessment tools to determine which best predicts death or major complications after cardiac surgery or transcatheter intervention. the population of interest is elderly patients with severe aortic stenosis undergoing surgical or transcatheter aortic valve replacement. the frailty assessment tools under investigation include composite frailty scales, physical performance tests, muscle mass, and biomarker expression. the overall objective is to improve our ability to predict risk by measuring frailty using the optimal tool in elderly cardiovascular patients.


Eligibility criteria:
inclusion criteria: 1. age ≥70 years (a site-specific substudy at the jgh will enroll ages ≥21 years) 2. severe as 3. referred for surgical or transcatheter avr (with or without concomitant revascularization) 4. signed informed consent exclusion criteria: 1. emergency surgery 2. clinical instability: decompensated heart failure, active ischemia, unstable vital signs 3. severe neuropsychiatric impairment 4. not english or french speaking 5. replacement of \>1 valve or aortic surgery

Keywords: aortic stenosis aortic valve replacement transcatheter aortic valve implantation outcomes frailty elderly
total tubeless percutaneous nephrolithotomy without a ureteral catheter

Conditions: Nephrolithotomy, Percutaneous; Kidney Calculi

Summary: total tubeless percutaneous nephrolithotomy (pcnl) is a modified surgical method of pcnl surgery, that is, there is no indwelling nephrostomy tube and double-j tube during pcnl surgery. compared with traditional pcnl surgery, it has the advantages of reducing pain, shortening operation time and reducing operation cost. since this procedure was first performed in 2004, several randomized clinical studies have verified the safety and efficacy of total tubeless pcnl. conventional total tubeless pcnl surgery requires the patient to first undergo retrograde transurethral ureteroscopic insertion of the ureteral catheter in the lithotomy position, and then change the patient to the prone position. however, a large number of literature reports and the surgical experience of pcnl in the past 20 years tell the investigators that the reverse insertion of ureteral catheter can cause many recent surgical complications.the study planned to perform the operation in the prone position without reverse insertion of a ureteral catheter in the total tubular pcnl surgery.

the purpose of this single-center, single-blind, randomized trial was to investigate whether without retrograde insertion of a ureteral catheter is appropriate for total tubeless percutaneous nephrolithotomy. it is planned to start in october 2022 and is expected to end in october 2024. based on inclusion and exclusion criteria, 100 subjects were expected to be recruited. in a parallel group design, subjects were randomly assigned to two groups: the experimental group received total tubeless pcnl without reverse insertion of a ureteral catheter , and the control group received conventional total tubeless pcnl. the primary end point of the study was the incidence of postoperative complications according to the modified clavien-dindo complication grading system. secondary end points included stone-free rate, operation time, length of hospital stay, and medical costs. measurement data were expressed as mean ± standard deviation (x ± s), and student's t-test was used for intergroup comparisons. the counting data were expressed as frequency and percentage, and the chi-squared or fisher's exact probability test were used for intergroup comparisons. the rank-sum test was used for grade data. p\<0.05 was considered statistically significant.

Eligibility criteria:
inclusion criteria: * patients with kidney stones who met the indications for pcnl surgery. * the maximum diameter of calculi was less than 35 mm. * the width of hydronephrosis effusion was less than 25mm. exclusion criteria: * patients with infectious calculi confirmed by preoperative ct examination and blood biochemical indexes. * patients with severe cardiac and pulmonary insufficiency, coagulation dysfunction and other obvious surgical contraindications. * patients with previous history of pcnl surgery on the affected side or nephrotomy. * patients with indwelling double j tube or nephrostomy tube before operation. * patients with renal trauma or congenital anomalies of urinary system.
ultrasound-guided selective supraclavicular nerve block for postoperative pain control in pediatric patients.

Conditions: Cancer Pediatric

Summary: this prospective randomized controlled trial aims to investigate the effect of ultrasound-guided selective supraclavicular nerve block on pain control after hickman catheter, chemoport, or perm cath insertion in children.

pediatric patients undergoing surgical insertion of a hickman catheter, chemoport, or permcath are randomly assigned to a test group (ultrasound-guided selective supraclavicular nerve block with ropivacaine) and a control group (nerve block is not performed). immediately after induction of general anesthesia, in the test group, the supraclavicular nerve block was selectively performed using ultrasound using 0.1ml/kg of 0.5% ropivacaine (maximum dose: 5ml), and the nerve block was not completed in the control group. after that, a hickman catheter, chemoport, or permcath is surgically inserted in the usual way and allowed to recover from anesthesia. the pain score is evaluated between 10 and 30 minutes of entering the recovery room (1 hour after the procedure) and 1 hour, 3 hours, and 24 hours after leaving the recovery room by another research team who is unaware of the group assignment. in addition, the use of additional analgesic drugs and related side effects were collected before discharge.

Eligibility criteria:
inclusion criteria: * pediatric patients receiving hickman catheter, chemoport, or perm cath implantation (3 years ≤, \<18 years) * one or more of the parents (or guardians), after hearing and understanding a sufficient explanation about this clinical trial, decides to participate voluntarily and agrees in writing to abide by the precautions * in the case of a study subject aged seven years or older, a person who voluntarily decides to participate in this clinical trial and agrees in writing to abide by the precautions after hearing and understanding a sufficient explanation about this clinical trial exclusion criteria: * patients who undergo surgery other than the surgery. * patients with diseases whose sensitivity to pain is different from that of the general public * unstable vital signs (heart rate, blood pressure) * general contraindications of ropivacaine * patients with a history of allergy to opioids * severe renal dysfunction (creatinine\> 3.0 mg/dl) * severe liver dysfunction (aspartate transaminase \> 120 unit/l, alanine aminotransferase \> 120 unit/l) * peripheral nervous system abnormalities * at risk of malignant hyperthermia * other cases that the researcher judges to be inappropriate

Keywords: selective supraclavicular nerve block postoperative pain control hickman catheter chemoport perm cath
placental volume, flow, and vascularity study

Conditions: Pre-Eclampsia

Summary: the purpose of this preliminary study is to implement an automated and standardized computer-based method that accurately measures placental volume, blood flow, and vascularity. this will be accomplished by using the digital data obtained at the time of a first-trimester 3d image volume. this information will then be used to further investigate whether placental volume, blood flow, and vascularity can be used to predict the risk of preeclampsia in conjunction with maternal history and serum blood markers obtained at the time of their ultrasound.

preeclampsia is defined as a multi-system disorder typically characterized by hypertension, proteinuria, and/or end organ damage. preeclampsia can develop rapidly at any time after 20 weeks gestation and into the postpartum period and can at times lead to systemic complications and even death. preeclampsia continues to be a leading cause of maternal morbidity and mortality secondary to the development of hypertensive disorders, systemic inflammatory changes affecting the endothelium, and hemorrhagic complications. it also contributes indirectly to neonatal morbidity and mortality by leading to premature delivery. our current ability to screen patients for the risk of developing preeclampsia relies on clinical factors as recommended by acog and the usphs. at this time, if a patient is deemed high risk, our only intervention for prevention of preeclampsia is to prescribe low-dose aspirin. being able to identify the population at higher risk for preeclampsia would allow for implementation of new management options among these persons. the purpose of this preliminary study is to implement an automated and standardized computer-based method that accurately measures placental volume, blood flow, and vascularity. this will be accomplished by using the digital data obtained at the time of a first-trimester 3d image volume. this information will then be used to further investigate whether placental volume, blood flow, and vascularity can be used to predict the risk of preeclampsia in conjunction with maternal history and serum blood markers obtained at the time of their ultrasound.

Eligibility criteria:
inclusion criteria: * singleton gestation * qualify for a first-trimester screen at the time of enrollment. criteria for the screen include pregnancy with gestational age between 10 weeks 3 days and 13 weeks 6 days of gestation as well as a crown-rump length between 40 and 84 mm. * complete a first-trimester ultrasound at the qualifying m health fairview maternal fetal medicine clinics, which include university riverside, ridges, south dale, and health east sites * provide a blood sample for either completion of the first-trimester screen and/or for the completion of the research study exclusion criteria: * multi-fetal gestation or pregnancy with major fetal congenital anomalies and/or known fetal aneuploidy * unwilling to complete a first-trimester ultrasound and/or unwilling to provide a serum sample
evaluating the link between neighborhood environments and obesity among african american women

Conditions: Obesity

Summary: african american women have higher rates of obesity than women of any other racial or ethnic group in the united states. obesity can have many causes, including genetic and environmental factors. this study will examine how neighborhood environments influence the occurrence of obesity among african american women.

obesity, which leads to higher rates of diabetes, cancer, and heart disease, is an increasingly important public health problem. in 2000, over 78% of african american women were overweight, and over 50% were obese. several factors can contribute to obesity, including genetics, diet, and environmental factors. individuals who live in an environment in which it is difficult to maintain an active lifestyle are more prone to obesity. the black women's health study (bwhs) is an extensive long-term study that is gathering data from women across the country to examine the occurrence of various diseases among african american women. using bwhs study data and specific information on participants' neighborhoods, including street layout and the presence of sidewalks, this study will determine if neighborhood environments influence the prevalence of obesity among african american women. this study will use already-collected data on physical activity and body mass index of bwhs study participants who live in new york, los angeles, and chicago; there are no additional study visits specifically for this study. a transportation and urban planning expert will compile data regarding the pedestrian environment of neighborhoods in all three cities, including the nature and density of land use, proximity to parks, presence of sidewalks, speed and volume of traffic, and street structure. census data regarding participants' socioeconomic status will also be collected.

Eligibility criteria:
inclusion criteria: * participating in the bwhs study * residing in new york, los angeles, or chicago

Keywords: body mass index